A review of etripamil: A new paradigm for treating paroxysmal supraventricular tachycardia for an informed, shared decision
Access to this document is restricted. Some items have been embargoed at the request of the author, but will be made publicly available after the "No Access Until" date.
During the embargo period, you may request access to the item by clicking the link to the restricted file(s) and completing the request form. If we have contact information for a Cornell author, we will contact the author and request permission to provide access. If we do not have contact information for a Cornell author, or the author denies or does not respond to our inquiry, we will not be able to provide access. For more information, review our policies for restricted content.
Paroxysmal supraventricular tachycardia (PSVT) is associated with significant morbidity and affects 1 in 300 people. This article reviews the contemporary management of PSVT and the potential role of intranasal etripamil, a recently FDA-approved intranasal calcium channel blocker that can be used to safely and effectively terminate PSVT in an outpatient setting and avoid urgent medical attention. When combined with the use of wearable devices, this paradigm shift of enabling patients to self-treat PSVT with an on-demand therapy provides another option to be considered in shared-decision making for PSVT management.